ADB-FUBINACA Powder is a designer drug identified in synthetic cannabis blends in Japan in 2013.The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively.ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.
Active substances in ADB-FUBINACA
Contains one gramm of min 99,8%+ pure ADB-FUBINACA per order unit.
Dosage of ADB-FUBINACA
There is no recomended dose since ADB-FUBINACA is not for human consumption but is sold only as a research chemical as legal high for research purpose.
Effects of ADB-FUBINACA :
The clinical effects of most new designer drugs like ADB-FUBINACA can be described as either hallucinogenic, stimulant, or opioid-like. They may also have a combination of these effects due to designer side-chain substitutions.
Side effects of ADB-FUBINACA
Like other designer drugs the use of ADB-FUBINACA can cause strong side effects; the substance is not clinically tested nor licensed in any way as a product for human consumption! Therefore ADB-FUBINACA is NOT FOR HUMAN CONSUMPTION but as LEGAL HIGH for SCIENTIFICAL RESEARCH ONLY!
How to store ADB-FUBINACA
Keep ADB-FUBINACA below 30 degrees celsius. Store ADB-FUBINACA in the original package, protect from direct sunlight and moisture.